- Report
- January 2022
- 150 Pages
Global
From €5246EUR$5,950USD£4,607GBP
- Report
- August 2022
- 115 Pages
Global
From €3967EUR$4,500USD£3,485GBP
- Report
- November 2023
- 135 Pages
Global
From €3526EUR$4,000USD£3,097GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €1940EUR$2,200USD£1,704GBP
€2424EUR$2,750USD£2,129GBP
- Report
- January 2024
- 250 Pages
Global
From €5607EUR$6,360USD£4,925GBP
€7009EUR$7,950USD£6,156GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2292EUR$2,600USD£2,013GBP
€2865EUR$3,250USD£2,517GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €1940EUR$2,200USD£1,704GBP
€2424EUR$2,750USD£2,129GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €1940EUR$2,200USD£1,704GBP
€2424EUR$2,750USD£2,129GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €1940EUR$2,200USD£1,704GBP
€2424EUR$2,750USD£2,129GBP
- Report
- August 2022
- 181 Pages
Global
From €5290EUR$6,000USD£4,646GBP
€6612EUR$7,500USD£5,808GBP
- Report
- August 2022
- 218 Pages
Global
From €5290EUR$6,000USD£4,646GBP
€6612EUR$7,500USD£5,808GBP
- Report
- May 2024
- 130 Pages
Global
From €4870EUR$5,524USD£4,278GBP
€5730EUR$6,499USD£5,032GBP
- Report
- May 2024
- 134 Pages
Global
From €4870EUR$5,524USD£4,278GBP
€5730EUR$6,499USD£5,032GBP
- Report
- February 2023
- 143 Pages
North America
From €3042EUR$3,450USD£2,671GBP
- Report
- January 2023
- 174 Pages
Global
From €3923EUR$4,450USD£3,446GBP
- Report
- August 2024
- 93 Pages
Global
From €3500EUR$4,253USD£3,182GBP

Treprostinil is a drug used to treat respiratory diseases such as pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is a prostacyclin analogue, meaning it works by mimicking the effects of prostacyclin, a naturally occurring hormone in the body that helps to regulate blood pressure in the lungs. Treprostinil is administered through a variety of methods, including oral tablets, subcutaneous injections, and inhalation. It is also available in a topical form for the treatment of Raynaud's phenomenon.
Treprostinil is a relatively new drug, having been approved by the FDA in 2002. It is used to treat a variety of respiratory diseases, including PAH, CTEPH, and Raynaud's phenomenon. It is also used to treat other conditions such as sickle cell anemia and cystic fibrosis.
The treprostinil market is a growing one, with many companies offering products and services related to the drug. Some of these companies include United Therapeutics, Actelion Pharmaceuticals, GlaxoSmithKline, and Pfizer. Show Less Read more